NCT00356356View on ClinicalTrials.gov

16.0040 Ankylosing Spondylitis Study

PHASE3CompletedINTERVENTIONAL

Enrollment

257

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

August 31, 2006

Study Completion Date

September 30, 2006

Conditions

Ankylosing Spondylitis

Interventions

DRUG

Etanercept

Etanercept 50 mg/wk administered as 2-25 mg SQ injections at separate injection sites

Sponsors

Lead Sponsor

Collaborators (1)

Immunex Corporation

All Listed Sponsors

collaborator

Immunex Corporation

INDUSTRY

lead

Amgen

INDUSTRY